Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2006

View Archived Issues

Gene therapy for spinal muscular atrophy / News in context

MAP Pharmaceuticals closes Series C financing

Callisto licenses degrasyns from M.D. Anderson

Durect expands SABER-Bupivacaine development program

Abbott highlights fourth quarter achievements

Bristol-Myers Squibb recaps recent events

New treatments for cancer covered in recent patents

Immunosuppressive activity of a newly isolated natural product

New compounds display dual BLT/TRPV1 antagonism

FDA Advisory Committee sets date for Tysabri review in MS

Amendment to BLP-25 Liposome Vaccine licensing agreement

Phase I study begins for Nanoplatin

First animal efficacy data for PhGalpha1

Photofrin studied for superficial cancerous and precancerous lesions of the mouth

Japanese manufacturing approval for Loxonin poultice

Pharmexa begins phase I study for HIV vaccine candidates

European orphan drug designation for 1D09C3 in CLL

CIP-Tramadol ER NDA planned for Q2 2006

Japanese filing for nateglinide in combination with biguanide agents

Creatine safe in Huntington's disease; further study under way

Bortezomib sensitizes multiple myeloma to radiation in vivo

Recent patents cover therapeutic agents for neurological disorders

Novel antiinfective agents described in recent patents

Remicade recommended for approval for ulcerative colitis in Europe

Avanir submits expanded Neurodex NDA

European CHMP hands down positive opinion for Lyrica in GAD

European approval for Ionsys in postoperative pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...